Senti Biosciences, Inc. (SNTI)
(Delayed Data from NSDQ)
$2.27 USD
-0.08 (-3.40%)
Updated Jul 24, 2024 04:00 PM ET
After-Market: $2.24 -0.03 (-1.32%) 7:58 PM ET
3-Hold of 5 3
F Value D Growth B Momentum F VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
SNTI 2.27 -0.08(-3.40%)
Will SNTI be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for SNTI based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for SNTI
Senti Bio (SNTI) Rises as FDA Clears IND for Cancer Candidate
Senti Biosciences, Inc. (SNTI) Reports Q2 Loss, Misses Revenue Estimates
SNTI: What are Zacks experts saying now?
Zacks Private Portfolio Services
Urogen Pharma (URGN) Reports Q2 Loss, Tops Revenue Estimates
Bionano Genomics, Inc. (BNGO) Reports Q2 Loss, Tops Revenue Estimates
Sangamo Therapeutics (SGMO) Reports Q2 Loss, Misses Revenue Estimates
Other News for SNTI
Senti Biosciences Inc trading halted, news pending
Senti Bio Announces Reverse Stock Split
Senti Bio announces 1-for-10 reverse stock split
Why Is Beyond Air (XAIR) Stock Down 22% Today?
Why Is Faraday Future (FFIE) Stock Down 27% Today?